The company announced the results during trading hours yesterday, 29 May 2008, when the stock declined 2.55% to Rs 244.45.

Meanwhile, the BSE Sensex was up 96.69 points, or 0.59%, to 16,412.95.

On BSE, 3,717 shares were traded in the counter. The scrip had an average daily volume of 49.83 lakh shares in the past one quarter.

The stock hit a high of Rs 250 and a low of Rs 246.10 so far during the day. The stock had a 52-week high of Rs 330 on 16 Aril 2008 and the stock hit a 52-week low of Rs 106.50 on 24 March 2008.

The mid-cap company had outperformed the market over the past one month till 29 May 2008, gaining 2.05% compared to the Sensex’s decline of 5.62%. It had also outperformed the market in the past one quarter, declining 2.94% compared to Sensex’s decline of 7.18%.

The company’s current equity is Rs 65.86 crore. Face value per share is Rs 10.

The current price of Rs 250 discounts its Q4 March 2008 annualised EPS of Rs 9.63, by a PE multiple of 25.96.

Orchid Chemicals & Pharmaceuticals’ net profit fell 34.7% to Rs 15.85 crore on 55.9% increase in net sales to Rs 379.19 crore in Q4 March 2008 over Q4 March 2007.

On 20 February 2008, Orchid Chemicals & Pharmaceuticals received approval from the US Food & Drug Administration (US FDA) for its abbreviated new drug application for cefuroxime axetil tablets.

On 14 February 2008, the company received approval from the US FDA for its abbreviated new drug application for Granisetron Hydrochloride tablets.

In January 2008, the company announced that its formulation facilities, comprising of cephalosporin and penicillin plant had received approved by the Medicines Control Council, South Africa.

The company is engaged in manufacturing and selling pharmaceuticals ingredients and finished dosage forms. It focuses on the cephalosporin range of antibiotics. The company exports to Asia Pacific, Europe, Middle East, South and Central America, North America and Commonwealth of Independent States (CIS) Countries.